Johnson & Johnson was founded in 1886 and is headquartered in New Brunswick, US
Report incorrect company information
Key People/Management at Johnson & Johnson
Alex Gorsky
Chairman, Board of Directors and Chief Executive Officer
Dominic J. Caruso
Executive Vice President, Chief Financial Officer
Joaquin Duato
Executive Vice President and Worldwide Chairman, Pharmaceuticals
Ashley McEvoy
Company Group Chairman, Consumer Medical Devices
Jorge Mesquita
Executive Vice President, Worldwide Chairman, Consumer
Sandra E. Peterson
Group Worldwide Chair
Report incorrect company information
Johnson & Johnson Office Locations
Johnson & Johnson has offices in Neenah, Solothurn, Zug, Dhaka and in 24 other locations
New Brunswick, US (HQ)
One Johnson & Johnson Plaza
Greenville, US
204 Greenville Blvd SW
Solothurn, CH
21 Luzernstrasse
Zug, CH
Gubelstrasse 34, 6300
Report incorrect company information
Johnson & Johnson Financials and Metrics
Johnson & Johnson Revenue
Johnson & Johnson's revenue was reported to be $71.89 b in FY, 2017 which is a 2.6% increase from the previous period.
| USD | |
|---|---|
Net income (Q1, 2019) | 4.4 b |
Market capitalization (18-Jul-2018) | 342.8 b |
Closing share price (18-Jul-2018) | 127.8 |
Cash (1-Apr-2018) | 14.6 b |
EV | 358 b |
Johnson & Johnson's current market capitalization is $342.8 b.
Annual
Quarterly
| USD | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 17.4 b | 17.8 b | 17.1 b | 17.5 b | 18.5 b | 17.8 b | 17.8 b | 18.8 b | 19.7 b | |
Cost of goods sold | 5.3 b | 5.4 b | 5.2 b | 5.3 b | 5.3 b | 5.5 b | 5.4 b | 5.8 b | 6.9 b | 6.6 b |
Gross profit | 12.1 b | 12.4 b | 11.9 b | 12.2 b | 13.1 b | 12.3 b | 12.4 b | 13 b | 12.7 b | |
Gross profit Margin, % | 70% | 70% | 69% | 70% | 71% | 69% | 70% | 69% | 65% |
Annual
| USD | FY, 2013 | FY, 2014 | FY, 2016 | FY, 2017 |
|---|---|---|---|---|
Cash | 20.9 b | 14.5 b | 13.7 b | 19 b |
Accounts Receivable | 11.7 b | 11 b | 10.7 b | 11.7 b |
Prepaid Expenses | 4 b | 3.5 b | 3 b | 3.3 b |
Inventories | 7.9 b | 8.2 b | 8.1 b | 8.1 b |
Quarterly
| USD | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|
Cash | 12 b | 10.6 b | 13.6 b | 13.9 b | 18.6 b | 18.2 b | 20.9 b | 12.6 b | 15.7 b | 14.6 b |
Accounts Receivable | 11.5 b | 12 b | 11.4 b | 11.4 b | 12.1 b | 11.8 b | 12.3 b | 13.3 b | 13.2 b | |
Prepaid Expenses | 3.7 b | 3.1 b | 3 b | 3.3 b | 3.1 b | 2.6 b | 2.8 b | 3 b | 2.9 b | |
Inventories | 8.1 b | 8.3 b | 8.2 b | 8.2 b | 8.5 b | 8.5 b | 8.9 b | 9.7 b | 9.5 b | 9 b |
Annual
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Net Income | 13.8 b | 16.3 b | 15.4 b | 16.5 b |
Depreciation and Amortization | 4.1 b | 3.9 b | 3.7 b | 3.8 b |
Inventories | (622 m) | (1.1 b) | (449 m) | (249 m) |
Accounts Payable | 1.8 b | 955 m | (3 m) | 656 m |
Quarterly
| USD | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|
Net Income | 4.3 b | 8.8 b | 12.2 b | 4.3 b | 8.5 b | 12.7 b | 4.4 b | 8.2 b | 12 b | 4.4 b |
Depreciation and Amortization | 895 m | 1.8 b | 2.7 b | 891 m | 1.8 b | 2.7 b | 912 m | 2.1 b | 3.8 b | |
Inventories | (276 m) | (537 m) | (719 m) | (190 m) | (443 m) | (408 m) | (368 m) | (421 m) | (193 m) | (322 m) |
Accounts Payable | (2.5 b) | (2.2 b) | 1.6 b | (2.3 b) | (1 b) | (1.2 b) | (2 b) | (1.2 b) | 339 m |
| USD | Y, 2018 |
|---|---|
EV/CFO | 99.3 x |
Financial Leverage | 2.5 x |
Johnson & Johnson Acquisitions / Subsidiaries
| Acquired Company | Date | Deal Size |
|---|---|---|
| Actelion Pharmaceuticals (2 k) | January 26, 2017 | $30 b |
| Abott Medical Optics | September 16, 2016 | $4.33 b |
| Vogue International | June 02, 2016 | $3.30 b |
| Novira Therapeutics | November 08, 2015 | |
| XO1 | March 20, 2015 | |
| Alios BioPharma | September 30, 2014 | $1.75 b |
| Aragon Pharmaceuticals | June 17, 2013 | $1 b |
| Acclarent | ||
| Advanced Sterilization Products Services Inc. | ||
| ALZA Corporation |
Johnson & Johnson Revenue Breakdown
Johnson & Johnson revenue breakdown by business segment: 18.5% from Consumer, 46.5% from Pharmaceutical and 34.9% from Medical Devices
Report incorrect company information
Johnson & Johnson Online and Social Media Presence
92.42k Twitter followers
Johnson & Johnson has 92.42k number of Twitter Followers. The number of followers has decrease 0.4% month over month and grown 1% quarter over quarter
781.69k Facebook likes
Johnson & Johnson has 781.69k number of Facebook Likes. The number of likes has grown 0.1% month over month and grown 0.4% quarter over quarter
Report incorrect company information
Johnson & Johnson Company Life and Culture
Report incorrect company information